Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 13;11(10):e048206.
doi: 10.1136/bmjopen-2020-048206.

Screening for SARS-CoV-2 infection in asymptomatic individuals using the Panbio COVID-19 antigen rapid test (Abbott) compared with RT-PCR: a prospective cohort study

Collaborators, Affiliations

Screening for SARS-CoV-2 infection in asymptomatic individuals using the Panbio COVID-19 antigen rapid test (Abbott) compared with RT-PCR: a prospective cohort study

Beatrice Winkel et al. BMJ Open. .

Abstract

Background: Antigen-based point-of-care tests for identification of SARS-CoV-2 may markedly enhance effectiveness of population-based controlling strategies. Previous studies have demonstrated >70% sensitivity and high specificity compared with reverse transcriptase real-time PCR (RT-PCR) in symptomatic individuals, but test performance for asymptomatic individuals is unknown.

Methods: Test performance of the Panbio COVID-19 Ag Rapid Test (Abbott) was compared with RT-PCR in a longitudinal cohort study of asymptomatic football players and staff members of professional football clubs. Based on timing of symptoms and prior and subsequent test results, positive RT-PCR tests were categorised as presymptomatic, early or late infection, or persistent RNA shedding.

Findings: 2425 tests were performed in 824 individuals, of which 52 (6.3%) were SARS-CoV-2 positive based on RT-PCR. There were 2406 paired sets from asymptomatic subjects for analysis. Sixteen Panbio tests were inconclusive, for which sensitivity analyses were performed (considering results as either positive or negative or being excluded). Sensitivity of Panbio for screening of asymptomatic individuals ranged from 80.0% (61.4-92.3) to 86.67% (69.2-96.2) and specificity from 99.53% (95% CI 99.2 to 99.8) to 100% (95% CI 99.8 to 100). Sensitivity of Panbio to detect subjects with presymptomatic/early infection (n=42) ranged from 81.82% (95% CI 67.3 to 91.8) to 90.91% (95% CI 78.3 to 97.5) with specificity always above 99%.

Interpretation: The Panbio COVID-19 Ag rapid test identifies 81%-90% of presymptomatic and early asymptomatic SARS-CoV-2 infections with high specificity. This test may therefore be adopted in testing strategies such as targeted screening of specific populations where prevalence is low.

Keywords: COVID-19; diagnostic microbiology; public health; virology.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Inclusion diagram. Diagram showing the flow of participants in the study.

References

    1. Kretzschmar ME, Rozhnova G, Bootsma MCJ, et al. . Impact of delays on effectiveness of contact tracing strategies for COVID-19: a modelling study. Lancet Public Health 2020;5:e452–9. 10.1016/S2468-2667(20)30157-2 - DOI - PMC - PubMed
    1. Furukawa NW, Brooks JT, Sobel J. Evidence supporting transmission of severe acute respiratory syndrome coronavirus 2 while presymptomatic or asymptomatic. Emerg Infect Dis 2020;26. 10.3201/eid2607.201595 - DOI - PMC - PubMed
    1. Gremmels H, Winkel BMF, Schuurman R. Real-life validation of the Panbio COVID-19 antigen rapid test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection. Eclin Med. - PMC - PubMed
    1. Bulilete O, Lorente P, Leiva A, et al. . Panbio™ rapid antigen test for SARS-CoV-2 has acceptable accuracy in symptomatic patients in primary health care. J Infect 2021;82:391–8. 10.1016/j.jinf.2021.02.014 - DOI - PMC - PubMed
    1. Alemany A, Baró B, Ouchi D, et al. . Analytical and clinical performance of the panbio COVID-19 antigen-detecting rapid diagnostic test. J Infect 2021;82:186–230. 10.1016/j.jinf.2020.12.033 - DOI - PMC - PubMed

Substances